Loading…
Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ‐67657, a p38 MAP‐kinase inhibitor, on LPS‐hyporesponsiveness
SUMMARY In the present study, we investigated the effect of RWJ‐67657, a p38 MAP kinase inhibitor, upon in vivo LPS‐induced monocyte cytokine production and upon monocyte LPS‐hyporesponsiveness. Thirty minutes before a single injection of LPS (4 ng/kg BW), healthy male volunteers received a single o...
Saved in:
Published in: | Clinical and experimental immunology 2002-02, Vol.127 (2), p.337-343 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | SUMMARY
In the present study, we investigated the effect of RWJ‐67657, a p38 MAP kinase inhibitor, upon in vivo LPS‐induced monocyte cytokine production and upon
monocyte LPS‐hyporesponsiveness. Thirty minutes before a single injection of LPS
(4 ng/kg BW), healthy male volunteers received a single oral dose of RWJ‐67657 at
increasing dosages (0–1400 mg). Blood samples (pre‐medication, 3, 6 and 24
h after LPS) were immediately incubated with LPS (reflecting LPS‐hyporesponsiveness)
or without LPS (reflecting in vivo monocyte stimulation) for 4 h at 37°C.
Following red blood cells lysis and white blood cell permeabilization, cells were
labelled with α‐CD14‐FITC and α‐IL‐1β, α‐IL‐12 or α‐TNFα
(PE‐labelled), fixed, and analysed using flow cytometry. In vivo LPS injection
resulted in an increased percentage of circulating monocytes producing IL‐1β,
TNFα and IL‐12 only at 3 h after the LPS injection. This was dose‐dependently
inhibited by RWJ‐67657 treatment. LPS‐hyporesponsiveness to in vitro LPS treatment
was most prominent at 3 and 6 h after the in vivo LPS injection; compared
with pre‐medication monocytes, at these intervals a reduced percentage of monocytes
produced IL‐1β, TNFα or IL‐12 after the in vitro LPS stimulus. At
t = 6 h, this LPS‐hyporesponsiveness could dose‐dependently be inhibited by RWJ‐67657
treatment of the volunteers. We therefore conclude that p38 MAP kinase inhibition
with RWJ‐67657 inhibited monocyte production of cytokines following in vivo LPS injection. Treatment with RWJ‐67657 also reversed the LPS‐hyporesponsiveness. Whether this result can be extended to the clinical situation remains to be elucidated. Patients with sepsis or an otherwise high risk for multi‐organ failure are potential study groups. |
---|---|
ISSN: | 0009-9104 1365-2249 |
DOI: | 10.1046/j.1365-2249.2002.01765.x |